queensland molecular tumour board · herrera-abreu mt et.al early adaptation and acquired...
TRANSCRIPT
4/12/19
1
10th April 2019Room 2004, TRI, Princess Alexandra Hospital,
Woolloongabba, QLD
Queensland Molecular Tumour Board
Patient 46 yr. old femaleSelf-detected L breast mass
MMG/US March 2017: 40mm lesion mediallyCore Box: invasive Ca
Medical History• Chronic R breast abscess, surgically excised• Obesity• Asthma• HTN• Previous IVDU. On methadone program
Family History
• Not in contact with mother, but thinks she has had breast & ?ovarian ca• Maternal aunt RIP breast cancer age ~30 years
4/12/19
2
Staging scans: Nonspecific 7mm LUL nodule.
WLE/SLNBx 18/07/17:
68mm, Gr 3 invasive ca, NST.ER + (60%), PR + (60%), HER2 non-amplified.Node negative.Positive margins, so underwent completion mastectomy.
Repeat CT staging Aug 2017 Increase in LUL nodule: pulmonary metastases.
Systemic therapy:Commenced ribociclib/letrozole/zoladex Aug 2017Continues on therapy
Molecular profile (re-analysis) 15/3/19
4/12/19
3
RSF1 expansion (diagnostic)Predicts lack of response to adjuvant tamoxifen, (n=672 but mutation is rare n=46) interaction( HR = 1.11 p = 0.09) Keilty et. al. PLoS One. 2013; 8(12): e81740.
TP53 Mutation: (diagnostic)Berns et. al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. (n=202) Cancer Res. 2000 Apr 15;60(8):2155-62.
• TP53 loss a predictor of poor response in the tamoxifen-treated group (OR, 0.29; 95% CI, 0.13-0.63; P = 0.0014)
• 66% of TP53- responded to tamoxifen, 31% of the patients TP53+ mutation responded to tamoxifen therapy
• Results only seen in ER+ patients• Response to Rad
TP53 cont. Berns et. al Figure 1: (right)
PFS (left) and survival after the start of tamoxifen treatment (right)
• TP53 gene status in all patients (ALL),
• high ER (>75 fmol/mg protein; ER-high),
• intermediate ER (10 > ER <75 fmol/mg protein; ER-medium),
• low ER (<10 fmol/mg protein; ER-low).
4/12/19
4
CCNE1 expansion (diagnostic): Preclinical data only may infer CDK4/6 inhibitor resistance (not on clinical repost)Herrera-Abreu MT et.al Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. Cancer Res. 2016 Apr 15;76(8):2301-13.
“CDK4/6 inhibition resistance resulted from bypass of cyclin D1-CDK4/6 dependency through selection of CCNE1 amplification or RB1 loss”
Did find addition information:Diagnostic for Poor P=0.001 Outcome (n=395)Ketomararsi N et. al. Engl J Med 2002; 347:1566-1575 (see figure right)
Similar findings in Ovarian Cancers
• BOLERO-1 and BOLERO-3 (Breast Cancer Trials of Oral Everolimus), evaluated the addition of everolimus to Trastuzumab and chemotherapy in HER2+ (n=549)
• PIK3CA in 30% of samples (HR, 0.67; 95% CI, 0.45 to 1.00)
• Patients without these molecular alterations showed essentially minimal PFS benefit from everolimus over placebo,
PIK3CA mutation
4/12/19
5
• PIK3CANCT03337724 - A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
NCT02506556 - Phosphatidylinositol 3-kinase (PI3K) Alpha inhibition In Advanced Breast Cancer
• FGFR1NCT02052778 - A Study of TAS-120 in Patients With Advanced Solid Tumors (NSW and VIC)
Phase 1 dose-escalation, dose-expansion, and Phase 2 study targeting tumors with FGF/FGFR aberrations. The purpose of the study is to evaluate the safety, tolerability, PK, pharmacodynamic, and anti-tumor activity of TAS-120 in patients with advanced solid tumors with and without FGF/FGFR-related abnormalities
Summary
• Mutations related to resistance to tamoxifen.
• CCNE1 (preclinical CDK4/6 resistance and poor outcome)
• FGFR1 expansion early trials only
• PIK3CA activating mutation
4/12/19
6
Breast Cancer Case Dr Poh See Choo
Sept 2017
49 year old Caucasian female presented in late 2017 with a history of uncharacteristically “blunt” comments at work. Friends recall her having “no filter” but patient having no recollection of these comments.
Driving deteriorated -> evaluation by optometrist - significant bilateral vision loss, L quadrananopia. Optometrist queried the possibility of aneurysms and after consultation with Mater Eye Clinic Reg -> Recommend urgent assessment at ED for CT scan.
CT brain revealed multiple cystic lesions consistent with brain metastasis.
Clinically no obvious primary
4/12/19
7
Investigations
Bilateral mammogram- no abnormality detected
Bilateral Ultrasound of the breast detected 3cm mass in the axillary
tail and 1cm intramammary lymph node.
Core biopsy of the primary breast lesion confirmed Grade 3 invasive
carcinoma which is ER+ve/PR+ve/HER2-ve. Fine needle biopsy of
the lymph node confirmed metastatic disease.
PET/CT scan confirmed brain metastasis only.
Brain MRI showed 4 large tumours – with surrounding oedema
• 2 in R occipito-temporal and 1 in L temporo-occipital area
• 1 in the L cerebellum, close to midline - ataxia
4/12/19
8
4/12/19
9
TREATMENT
Received 35-40Gy stereotactic radiotherapy in 10 # .Started on high dose Dexamtheasone to reduce oedema and prevent hydrocephalus
Endocrine therapy with Letrozole
Plan for 3 monthly scans-> responding to treatment on follow up scans
• Nov 2017 CT and Dec 2017 MRI brain• Jan 2018 and Apr 2018 MRI- brain ongoing response• CT scan- responding to treatment
4/12/19
10
4/12/19
11
April 2018
PET/CT scan and MRI revealed Liver and bony (scapula) mets
-> Fluorouracil, Epirubicin and Cyclophosphamide (FEC100-6 cycles every 3 weeks).
Samples sent for molecular profiling
4/12/19
12
4/12/19
13
4/12/19
14
Summary of Molecular Findings – Paul Leo
PIK3CA NP_006209.2:p.Asn345Phe
4/12/19
15
• BOLERO-1 and BOLERO-3 (Breast Cancer Trials of Oral Everolimus), evaluated the addition of everolimus to trastuzumab and chemotherapy in HER2+ (n=549)
• PIK3CA in 30% of samples (HR, 0.67; 95% CI, 0.45 to 1.00)• PTEN loss in 12% (HR, 0.54; 95% CI, 0.31 to 0.96) • PIK3CA and PTEN 3%
• Patients without these molecular alterations showed essentially minimal PFS benefit from everolimus over placebo,
Clinical Trials targeting PICK3CA
Brisbane
NSW-Peter Mac
NSW & VIS Exclude:Prior treatment with exemestaneBrain Mets
4/12/19
16
Trials for high TMB
• Trails for TNBC
• Solid tumors with High Tumor Mutational Burden (TMB-H)
Excelmetastatic
August 2018
PET/CT scan - no evidence of tumour in axilla or breast.
Liver lesion had reduced but still very active.
Based on PIK3CA mutation -aromatase inhibitor and Everolimus
4/12/19
17
4/12/19
18
Dec 2018
PET and MRI - remission – FDG showed inactivity in all sites
-> Continued on AI and Everolimus
4/12/19
19
4/12/19
20
March 2019
PET and MRI - liver met active again and a new lymph node adjacent to liver
Discontinued AI and Everolimus and commenced on Abraxane (Nab-Paclitaxel) for 3 months
Will evaluate response after 3 months and decide whether to resume Everolimus
4/12/19
21
4/12/19
22
Family history
16 years
d 72 yearsAlzheimers 60 years
d 67 yearsETOH
d 26 yearsPostnatal pulmonary Embolism
Germany (Ashkenazi Jewish) England/Scotland/Ireland
59 yrs 57 yrs 55 yrs
n
80 yrs
Positive family history of ca breast
46 yrs Dg Ca Breast 38 yrs
75 yrsDg Ca prostate 70 yrs
n
Dg Ca Breast 80
A+W
96 years75 yearsCongestive heart failure
Nov 2017 BRCA1/2 neg
CHEK2 pos
Ca Breast
March 2019 Consented to research protocol to determine CHEK2 status